Palvella Therapeutics (PVLA) to Post Earnings on Tuesday

Palvella Therapeutics (NASDAQ:PVLA) is expected to be announcing its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Palvella Therapeutics to post earnings of ($1.17) per share for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:30 AM ET.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). On average, analysts expect Palvella Therapeutics to post $-5 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Palvella Therapeutics Trading Down 7.4%

Shares of NASDAQ:PVLA opened at $139.04 on Friday. Palvella Therapeutics has a 1-year low of $34.57 and a 1-year high of $161.38. The firm has a market capitalization of $1.99 billion, a PE ratio of -33.34 and a beta of -0.20. The business’s 50 day moving average is $130.19 and its 200-day moving average is $118.29.

Insider Transactions at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total value of $476,360.46. Following the transaction, the chief operating officer directly owned 2,154 shares in the company, valued at $238,512.42. The trade was a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of PVLA. Group One Trading LLC grew its position in Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after acquiring an additional 200 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Palvella Therapeutics by 11.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,090 shares of the company’s stock valued at $429,000 after purchasing an additional 433 shares during the last quarter. Bank of America Corp DE raised its position in Palvella Therapeutics by 12.3% in the 3rd quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock valued at $294,000 after purchasing an additional 515 shares during the last quarter. Deutsche Bank AG boosted its stake in Palvella Therapeutics by 8.7% in the fourth quarter. Deutsche Bank AG now owns 6,594 shares of the company’s stock worth $690,000 after purchasing an additional 528 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in Palvella Therapeutics in the third quarter worth $36,000. Institutional investors own 40.11% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Stephens reaffirmed an “overweight” rating and issued a $220.00 target price on shares of Palvella Therapeutics in a research report on Thursday, May 21st. HC Wainwright reissued a “buy” rating and issued a $270.00 price target on shares of Palvella Therapeutics in a report on Wednesday, July 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. Wall Street Zen downgraded shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Finally, Chardan Capital upgraded shares of Palvella Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $199.53.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.